Gilead’s Trodelvy Strategy Helped By Phase II Bladder Cancer Data

 
• By Joseph Haas
  
Antibody-drug conjugate
Gilead continues working toward adding to ADC Trodelvy's label • Source: Shutterstock

More from Clinical Trials

More from R&D